Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination - PubMed
4 hours ago
- #vaccination
- #Alzheimer's disease
- #geriatrics
- High-dose influenza vaccination (H-IIV) is associated with significantly lower Alzheimer dementia (AD) risk compared to standard-dose vaccination (S-IIV) in adults aged 65 and older.
- The study, a retrospective cohort analysis using US health care claims data from 2014-2019, followed participants for up to 3 years post-vaccination.
- Significant AD risk reduction was observed during months 1-25 after H-IIV, with a minimum number needed to treat (NNT) of 185.2 at 25 months.
- Sex-stratified analysis showed risk reduction persisted longer in women (months 1-13, NNT = 416.7) than in men (months 17-24, significant only in intention-to-treat analysis, NNT = 232.6).
- The study provides Class II evidence supporting H-IIV's association with reduced incident dementia, but limitations include a follow-up period of ≤3 years and lack of data on sociodemographics, lifestyle, biomarkers, and mortality.
- Further research is needed to determine if the observed protection is due to reduced influenza infection or other mechanisms.